Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin (N2R)

This study has been completed.

Sponsor:

Collaborators:

Mahidol University

Chulalongkorn University

Information provided by:

Bamrasnaradura Infectious Diseases Institute

ClinicalTrials.gov Identifier:

NCT00483054

First received: June 5, 2007

Last updated: November 21, 2011

Last verified: June 2009

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2010
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

No publications provided by Bamrasnaradura Infectious Diseases Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009 Jun 15;48(12):1752-9.

To Top